Navigation Links
Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays
Date:3/27/2009

Rapid, actionable intelligence in 2 hours

CHICAGO, March 27 /PRNewswire/ -- Celsis International plc (LSE: CEL.L), a global leader in rapid microbial detection solutions for industry, today announces the launch of Celsis ReACT(TM), the first easy-to-use RNA-based assay for detecting objectionable organisms quickly and definitively without the need for expensive equipment or specialized training.

Manufacturers of pharmaceutical, beauty and home care products using Celsis Rapid Detection systems for their primary screening of raw materials, in-process and finished goods can now utilize this new RNA-based assay to obtain a fast, 2-hour result on samples that test positive for microbial contamination. Celsis ReACT assays use proprietary selections of ribosomal RNA sequences to confirm or to rule out the presence of Gram-negative organisms, Staph. aureus, yeast and mold, and can be customized for facility-specific or wild strain organisms.

"Serious contamination events, while somewhat rare, do happen. When they occur they can cost companies hundreds of thousands, if not millions of dollars," explained Jay LeCoque, Celsis CEO. "We developed Celsis ReACT for our customers who have asked for a way to quickly and easily determine if they have an objectionable organism, so they can minimize the financial impact to their operations and bottom line."

The faster a company can confirm that a sample has been contaminated by an objectionable organism, the faster the contaminated batch can be stopped before it reaches the production line or, even worse, is released for sale. In addition, a faster reaction means fewer potentially contaminated additional batches will be produced, thus significantly reducing the financial impact of lost product and product disposal.

Celsis customers will be able to use Celsis ReACT following the primary Celsis AKuScreen(TM) assay, which definitively detects the presence or absence of microbial organisms in 18-24 hours instead of the typical 3-5 days for microbial limits testing. The same primary system has also been proven successful in equaling the traditional 14-day sterility test in less than half the time. Following a positive result on the Celsis primary system, the new Celsis ReACT assays use Celsis' existing instrument platform to provide rapid, actionable intelligence and secondary analysis within 2 hours.

"Celsis ReACT offers our customers the speed, simplicity and reliability of Celsis Rapid Detection systems combined with the precision of advanced molecular biology," said Lori Daane, Ph.D., a microbiologist and vice president of scientific affairs and customer service for Celsis Rapid Detection. The industry's easiest-to-use RNA system, Celsis ReACT uses simple protocols with user-friendly, color-coded steps. Basic measuring and pipetting skills are all that's required technically, and the Celsis system provides fast, clear results in two hours. With minimal training, existing customers can immediately adopt this new RNA-based testing system and begin to realize the benefits of fast, definitive results.

For more information about Celsis ReACT, visit www.celsis.com/react or contact Celsis Rapid Detection at +1 312 476 1282.

About Celsis Rapid Detection Systems

Celsis Rapid Detection systems provide significant economic value to manufacturers by significantly reducing the time required to test and release raw materials, in-process solutions and finished goods to market. Pharmaceutical and consumer products manufacturers using Celsis systems realize improved cash flow and reduce their inventory and working-capital requirements, while ensuring quality and increased responsiveness throughout the supply chain.

About Celsis International plc

Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries. Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers. Celsis' extensive client base includes many of the world's leading pharmaceutical and consumer products companies. The Company is listed on the London Stock Exchange (CEL.L).


'/>"/>
SOURCE Celsis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes
2. Celsis Launches RapiScreen(TM) Beverage Microbial Screening System
3. Celsis Receives Frost & Sullivan 2008 Best Practices Award
4. PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace
5. DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors
6. Lumenis(R) Introduces Cost-Saving Innovations at the 2009 American Academy of Dermatology (AAD) Annual Meeting
7. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
8. Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
9. Sigma-Aldrich Introduces MISSION(R) LentiPlex(TM) Pooled shRNA Libraries to Enable Rapid Whole Genome Screening in Primary Cells, Stem Cells or Tumor Cells
10. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
11. Max Muscle Introduces First-Ever Probiotics Protein Bar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2017)... ... September 17, 2017 , ... ... Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug ... Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second ...
(Date:9/14/2017)... , ... September 14, 2017 ... ... the launch of its CliniControl™ (CC) product portfolio, clinically-relevant starting and ancillary ... translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The CliniControl product portfolio ...
(Date:9/14/2017)... , ... September 14, 2017 , ... AIM Global, the ... Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. The ... provide benefits that decrease risk” and push the adoption of automated data collection systems ...
(Date:9/12/2017)... ... 12, 2017 , ... PhysIQ, a Chicago-based company that provides ... monitoring and clinical trial support, earned DPharm Idol 2017 honors at the 7th ... Launched in 2005, PhysIQ leverages artificial intelligence (AI) to empower digital health. The ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
Breaking Biology News(10 mins):